Akebia Therapeutics Inc (AKBA) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Akebia Therapeutics Inc   (NASDAQ: AKBA)


Akebia Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Akebia Therapeutics Inc's ROI in the second quarter of 2026?
Akebia Therapeutics Inc recorded a cumulative net loss of $-30 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -14.44%.

Within the Healthcare sector 235 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2968 to 3065.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 13.04 % 40.27 % 60.96 % 46.86 % 27.77 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 189 189 214 231 227
Return On Investment (TTM) -14.44 % -9.54 % -2.4 % -7.79 % -20.07 %
AKBA's Overall Ranking # 3065 # 2968 # 2318 # 2821 # 2975
Seq. Investment Change TTM -4.43 % -3.41 % 9.05 % 12.29 % 18.59 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -30 -21 -5 -16 -36

AKBA Company Profile >> Back to AKBA Roi Comparisons >> See Annual AKBA Return On Investment



Return On Investment AKBA's Ranking
Within: No.
Industry # 85
Sector # 236
Overall # 3065

Return On Investment Statistics
High Average Low
-2.4 %
-44.04 %
-98.18 %
(Dec 31 2025)   (Mar 31 2017)







Financial Statements
Akebia Therapeutics Inc's II. Quarter Investments $ 189 Millions AKBA's Balance sheet
Akebia Therapeutics Inc's II. Quarter Income $ -9 Millions Quarterly AKBA's Income Statement
AKBA's Income by Division See AKBA's Income by Division


AKBA Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 214 140 142 227 269
Y / Y Investment Growth 52.86 % -1.46 % -37.39 % -15.81 % -41.12 %
Net Income in Millions -5 -69 -52 -94 -283
Y / Y Net Income Growth - - - - -
Annual Return On Investment -2.5 % -49.67 % -36.61 % -41.6 % -105.12 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
AKBA's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for AKBA's Competitors
Subscribers only: Roi for Akebia Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for AKBA's Customers

Other Ratios
AKBA's Roa AKBA's Inventory Turnover Ratio AKBA's Growth Rates AKBA's Dividend Statistics
AKBA's Profitability Ratios AKBA's Asset Turnover Ratio AKBA's Dividend Growth
AKBA's Roe AKBA's Valuation Ratios AKBA's Financial Strength Ratios AKBA's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-09T01:58:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.